Showing 1 - 5 results of 5 for search 'Ingrid Kromann', query time: 0.05s Refine Results
  1. 1
    Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.

    Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. by David J M Lewis, Zhiming Huo, Susan Barnett, Ingrid Kromann, Rafaela Giemza, Eva Galiza, Maria Woodrow, Birgit Thierry-Carstensen, Peter Andersen, Deborah Novicki, Giuseppe Del Giudice, Rino Rappuoli

    Published 2009-09-01
    Get full text
    Article
  2. 2
    Availability and use of Standards in vaccine development

    Availability and use of Standards in vaccine development by Michael Selorm Avumegah, Giada Mattiuzzo, Anna Särnefält, Mark Page, Karen Makar, Janet Lathey, June Kim, Solomon Abebe Yimer, Danielle Craig, Ivana Knezevic, Valentina Bernasconi, Paul A. Kristiansen, Ingrid Kromann

    Published 2023-06-01
    Get full text
    Article
  3. 3
    A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

    A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area by Jemal Hussein, Martha Zewdie, Lawrence Yamuah, Ahmed Bedru, Markos Abebe, Alemnew F. Dagnew, Menberework Chanyalew, Asfawesen G. Yohannes, Jemal Ahmed, Howard Engers, T. Mark Doherty, Peter Bang, Ingrid Kromann, Søren T. Hoff, Abraham Aseffa

    Published 2018-01-01
    Get full text
    Article
  4. 4
    Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.

    Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, do... by Klaus Reither, Lynn Katsoulis, Trevor Beattie, Nicolene Gardiner, Nicole Lenz, Khadija Said, Elirehema Mfinanga, Christian Pohl, Katherine L Fielding, Hannah Jeffery, Benjamin M Kagina, Elisabeth J Hughes, Thomas J Scriba, Willem A Hanekom, Søren T Hoff, Peter Bang, Ingrid Kromann, Claudia Daubenberger, Peter Andersen, Gavin J Churchyard

    Published 2014-01-01
    Get full text
    Article
  5. 5
    A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

    A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolesce... by Linda-Gail Bekker, One Dintwe, Andrew Fiore-Gartland, Keren Middelkoop, Julia Hutter, Anthony Williams, April K. Randhawa, Morten Ruhwald, Ingrid Kromann, Peter L. Andersen, Carlos A. DiazGranados, Kathryn T. Rutkowski, Dereck Tait, Maurine D. Miner, Erica Andersen-Nissen, Stephen C. De Rosa, Kelly E. Seaton, Georgia D. Tomaras, M. Juliana McElrath, Ann Ginsberg, James G. Kublin

    Published 2020-04-01
    Get full text
    Article

Search Tools: